Dietary vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model

Nutrition and Cancer

Volumn 66, Issue 3, 2014, Pages 383-387

  Robinson, Cleo ^a   Woo, Samantha ^a   Nowak, Anna K ^a   Lake, Richard A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASBESTOS; COLECALCIFEROL; SELENIUM; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; LATENT PERIOD; MALE; MESOTHELIOMA; MINERAL INTAKE; MOUSE; NONHUMAN; OVERALL SURVIVAL; SURVIVAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIET THERAPY; DISEASE MODEL; MORTALITY; TRANSGENIC MOUSE;

MUS;

ANIMALS; ASBESTOS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; MESOTHELIOMA; MICE, TRANSGENIC; VITAMIN D;

EID: 84897370286     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.878733     Document Type: Article

References (28)

1. Mamede AC, Tavares SD, Abrantes AM, Trindade J, Maia JM, et al.: The role of vitamins in cancer: a review. Nutr Cancer 63, 479-494, 2012.
2. Gonzalez CA: Nutrition and cancer: the current epidemiological evidence. Br J Nutr 96(Suppl. 1), S42-S45, 2006.
3. Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353, 1591-1603, 2005. (Pubitemid 41434638)
4. Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, and Robinson BW: Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin Pharmacother 5, 2441-2449, 2004. (Pubitemid 39646507)
5. Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, et al.: Effects of treatment regimens on survival in patients with malignant pleuralmesothelioma. Eur Rev Med Pharmacol Sci 17, 19-24, 2013.
6. Kinnula VL: Oxidant and antioxidant mechanisms of lung disease caused by asbestos fibres. Eur Respir J 14, 706-716, 1999. (Pubitemid 29479741)
7. Robinson C, Walsh A, Larma I, O'Halloran S, Nowak AK, et al.: Mex-TAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer 47, 151-161, 2011.
8. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144, 646-674, 2011.
9. Fleet JC, DeSmet M, Johnson R, and Li Y: Vitamin D and cancer: a review of molecular mechanisms. Biochem J 441, 61-76, 2012.
10. Wang Y, Zhu J, and DeLuca HF: Where is the vitamin D receptor Arch Biochem Biophys 523, 123-133, 2012.
11. Braun N, Fritz P, Biegger D, Kimmel M, Reimold F, Ulmer C, et al.: Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum-implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int 31, 291-300, 2011.
12. Garg M, Lubel JS, Sparrow MP, Holt SG, and Gibson PR: Review article: vitamin D and inflammatory bowel disease-established concepts and future directions. Aliment Pharmacol Ther 36, 324-344, 2012.
13. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, et al.: The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68, 261-269, 2008.
14. Jeffery LE,Wood AM, Qureshi OS, Hou TZ, Gardner D, et al.: Availability of 25-hydroxyvitamin D3 to APCs controls the balance between regulatory and inflammatory T cell responses. J Immunol 189, 5155-5164, 2012.
15. Hummel DM, Thiem U, Hobaus J, Mesteri I, Gober L, et al.: Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. J Steroid Biochem Mol Biol 136, 284-288, 2013.
16. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, et al.: Dietary vitamin D(3) and 1,25-dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograftmodels of breast and prostate cancer. Endocrinology 153, 2576-2587, 2012.
17. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, et al.: The role of vitamin D in cancer prevention. Am J Public Health 96, 252-261, 2006. (Pubitemid 43167123)
18. Nair-Shalliker V, Armstrong BK, and Fenech M: Does vitamin D protect against DNA damage Mutat Res 733, 50-57, 2012.
19. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, et al.: A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 66, 10786-10794, 2006 (Pubitemid 44876974)
20. Robinson C, Woo S, Walsh A, Nowak AK, and Lake RA: The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer 64, 315-322, 2012.
21. Ahonen MH, Tenkanen L, Teppo L, Hakama M, and Tuohimaa P: Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847-852, 2000.
22. Krishnan AV, Trump DL, Johnson CS, and Feldman D: The role of vitamin D in cancer prevention and treatment. Rheum Dis Clin North Am 38, 161-178, 2012.
23. McCullough ML, Stevens VL, Patel R, Jacobs EJ,Bain EB, et al.: Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11, R64, 2009.
24. Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, et al.: Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 17, 889-894, 2008. (Pubitemid 351536420)
25. Irving AA, Halberg RB, Albrecht DM, Plum LA, Krentz KJ, et al.: Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models. Arch Biochem Biophys 515, 64-71, 2011.
26. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, et al.: Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100, 796-804, 2008. (Pubitemid 351809669)
27. Campbell FC, Xu H, El-Tanani M, Crowe P, and Bingham V: The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control. Biochem Pharmacol 79, 1-9, 2010.
28. Creaney J, Yeoman D, Demelker Y, Segal A,Musk AW, et al.: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3, 851-857, 2008.